CDT Equity Inc.
$1.23+2.50%(+$0.03)
TickerSpark Score
62/100
90
Valuation
65
Profitability
60
Growth
64
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CDT research report →
52-Week Range0% of range
Low $1.18
Current $1.23
High $1130.00
Companywww.conduitpharma.com
CDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C.
- CEO
- Andrew Regan
- IPO
- 2022
- Employees
- 6
- HQ
- Naples, FL, US
Price Chart
-99.89% · this period
Valuation
- Market Cap
- $5.98M
- P/E
- 2.88
- P/S
- 0.01
- P/B
- 0.04
- EV/EBITDA
- 13.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 36.93%
- Op Margin
- 6.44%
- Net Margin
- 2.38%
- ROE
- 2.59%
- ROIC
- 0.92%
Growth & Income
- Revenue
- $2.72B · 0.00%
- Net Income
- $237.52M · 1434.24%
- EPS
- $1500.00 · 129.23%
- Op Income
- $315.69M
- FCF YoY
- -84.51%
Performance & Tape
- 52W High
- $1130.00
- 52W Low
- $1.18
- 50D MA
- $5.77
- 200D MA
- $79.03
- Beta
- 1.57
- Avg Volume
- 97.64K
Get TickerSpark's AI analysis on CDT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | Regan Andrew | other | 100,000 |
| Mar 24, 26 | Regan Andrew | other | 147,401 |
| Mar 24, 26 | Regan Andrew | other | 147,401 |
| Apr 27, 26 | Olsen Ulrik K | other | 0 |
| Mar 17, 26 | Taylor Mark Andrew | other | 51,420,358 |
| Feb 19, 26 | Taylor Mark Andrew | other | 9,968,931 |
| Feb 19, 26 | Taylor Mark Andrew | other | 46,902 |
| Mar 17, 26 | Taylor Mark Andrew | other | 51,161,318 |
| Feb 19, 26 | Taylor Mark Andrew | other | 0 |
| Mar 17, 26 | Taylor Mark Andrew | other | 0 |
Our CDT Coverage
We haven't published any research on CDT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CDT Report →Similar Companies
HEPA+22.91%
Hepion Pharmaceuticals, Inc.
$0.09
XAGE+0.00%
Longevity Health Holdings Inc.
$0.32
ZVSA-2.65%
ZyVersa Therapeutics, Inc.
$0.18
COCH-1.35%
Envoy Medical, Inc.
$0.73
WORX+4.72%
SCWorx Corp.
$1.11
LIXT+6.26%
Lixte Biotechnology Holdings, Inc.
$5.60
NIVF-14.17%
NewGenIvf Group Limited
$0.74
PTPI+0.00%
Petros Pharmaceuticals, Inc.
$0.01